Musculoskeletal disorder

Option C: Alendronate is not effective in the treatment of an acute episode of gout, as it is primarily used for osteoporosis and does not address the inflammatory response associated with gout flares. Gout treatment focuses on reducing inflammation and pain during acute attacks.

Option A: Indometacin is a nonsteroidal anti-inflammatory drug (NSAID) that effectively reduces pain and inflammation during acute gout attacks, making it a suitable choice for treatment.

Option B: Naproxen, another NSAID, is also effective in managing pain and inflammation during acute gout episodes, providing symptomatic relief for patients.

Option D: Colchicine specifically targets the inflammatory process in gout and is effective in alleviating pain during acute attacks, making it a standard treatment option.

Takeaways: Understanding the pharmacological agents used in gout management is crucial, as effective treatment options like NSAIDs and colchicine are essential for addressing acute episodes, while medications like alendronate do not apply in this context.

Option D: All the above accurately reflects the adverse effects associated with penicillamine, which include thrombocytopenia, leucopenia, and immune complex glomerulonephritis. These effects are significant and require monitoring in patients receiving this medication due to its immunosuppressive properties and potential for renal complications.

Option A: Thrombocytopenia is a known adverse effect of penicillamine, but it is only one of several possible effects, not the complete picture.

Option B: Leucopenia is also an adverse effect of penicillamine, yet it does not encompass all the potential complications associated with the drug.

Option C: Immune complex glomerulonephritis is a serious complication linked to penicillamine use, but it is not the sole adverse effect.

Takeaways: Adverse effects of penicillamine include thrombocytopenia, leucopenia, and immune complex glomerulonephritis, necessitating careful monitoring and patient education regarding these risks, as outlined in NIH guidelines on penicillamine.

Option A: Serum creatine kinase levels are increased when a person has muscle damage, as CK is an enzyme released into the bloodstream following injury to muscle tissue. Elevated levels indicate muscle injury, which can occur from various causes such as trauma, strenuous exercise, or certain medical conditions.

Option B: Rheumatoid arthritis does not directly cause elevated serum creatine kinase levels. While it involves inflammation and joint damage, it primarily affects the joints rather than muscle tissue, which is where CK is released from.

Option C: Spondyloarthritis primarily affects the spine and joints, leading to inflammation but not typically resulting in elevated serum creatine kinase levels. CK elevation is more associated with direct muscle injury rather than joint inflammation.

Option D: Systemic lupus erythematosus can cause various systemic effects, but it does not directly lead to increased serum creatine kinase levels. The elevation of CK is specifically linked to muscle damage rather than autoimmune processes affecting other tissues.

Takeaways: Elevated serum creatine kinase levels are indicative of muscle damage, as CK is released from injured muscle tissue. Understanding this relationship is crucial for diagnosing conditions related to muscle injury, which requires monitoring of enzyme levels in clinical practice to assess muscle health.

Option A: Sulfinpyrazone does not cause hyperuricaemia; rather, it is a uricosuric agent that promotes the excretion of uric acid, thereby lowering serum uric acid levels. This makes it effective in treating gout and preventing hyperuricaemia.

Option B: Cytosine arabinoside can lead to hyperuricaemia due to the rapid cell turnover associated with the treatment of acute leukaemia, which increases uric acid production from nucleic acid breakdown.

Option C: Bendromethiazide, a thiazide diuretic, can cause hyperuricaemia by decreasing renal clearance of uric acid, leading to elevated serum levels.

Option D: Low-dose aspirin can also cause hyperuricaemia as it competes with uric acid for renal tubular secretion, reducing uric acid excretion and potentially increasing serum levels.

Takeaways: Understanding the pharmacological effects of medications like sulfinpyrazone, which promotes uric acid excretion, is crucial in managing conditions like gout and hyperuricaemia, requiring patient education on medication effects to ensure effective treatment strategies.

Option B: Spuriously increased serum creatinine does not apply as an adverse effect of indometacin. Indometacin is a nonsteroidal anti-inflammatory drug (NSAID) that can affect renal function, but it typically leads to an actual increase in serum creatinine rather than a spurious one, which is a misleading or false elevation not due to true renal impairment.

Option A: Biochemical hepatitis is a known adverse effect of indometacin, as it can cause liver enzyme elevations and liver toxicity in some patients, leading to biochemical hepatitis.

Option C: Antagonizes the antihypertensive effects of angiotensin-converting enzyme (ACE) inhibitors is accurate, as NSAIDs like indometacin can reduce the effectiveness of ACE inhibitors by causing renal vasoconstriction and sodium retention, which can lead to increased blood pressure.

Option D: Exacerbates cardiac failure is also true, as indometacin can cause fluid retention and worsen heart failure symptoms due to its effects on renal function and fluid balance.

Takeaways: Understanding the adverse effects of indometacin, particularly its potential to exacerbate renal issues and interact with other medications, is crucial for safe patient management, especially in those with pre-existing conditions. This requires careful monitoring of renal function and blood pressure when prescribing NSAIDs like indometacin.